DermatologyNews.net

Dermatology Xagena

Search results for "Adalimumab"

CHMP, the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency ( EMEA ), has issued a positive opinion recommending approval of Adalimumab ( Humi ...


Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


Results from a phase 3 pivotal study demonstrating that Adalimumab ( Humira ) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa ( HS ), specifi ...


Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis factor-alpha ( TNF-alpha ) inhibitors as a treatment for refractory uveitis is ...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with Adalimumab ( Humira ) has achieved at least a 75% improvement in ...